Objective To investigate the influencing factors for hepatitis C antibody and the preventive effect of hepatitis C in Yanbian Prefecture of China in the recent 7 years.Methods A total of 1184 residents in Yanbian were randomly selected in 2020, peripheral blood samples were collected, and the colloidal gold method was used to detect hepatitis C antibody. The positive rate of hepatitis C antibody in 2020 was compared with the data in 2013. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups, and then pairwise comparison was performed.Results The positive rate of hepatitis C antibody in Yanbian residents screened in 2020 was significantly lower than that in 2013 (6.42% vs 10.60%, χ2=11.212, P=0.001). The Fisher's exact test (2×C) was performed for the positive rate of hepatitis C antibody between different age groups in 2020, and the results showed that there was a significant difference between the 5 age groups (χ2=29.478, P < 0.001). Pairwise comparison after Bonferroni adjustment showed that there was a significant difference between the≥60 years group and the 50-59 years group, between the≥60 years group and the 40-49 years group, and between the≥60 years group and the 30-39 years group (χ2=11.268, 14.804, and 9.293, all P < 0.01), while there was no significant difference between the other groups (P > 0.01). The Chinese Korean population had a significantly higher positive rate of antibody than the non-Chinese Korean population (10.45% vs 5.50%, χ2=7.236, P=0.007). As for the farmers, the positive rate of hepatitis C antibody in 2020 was significantly lower than that in 2013 (7.16% vs 19.74%, χ2=36.604, P < 0.001). The positive rate of hepatitis C antibody in rural areas was significantly higher than that in urban areas (7.33% vs 4.26%, χ2=3.882, P=0.049).Conclusion The positive rate of hepatitis C antibody is mainly associated with age, nationality, occupation, and region. There is a reduction in the positive rate of hepatitis C antibody in Yanbian in the recent 7 years, suggesting that Yanbian Prefecture has achieved a marked effect in the prevention and treatment of hepatitis C.
PIETSCHMANN T, BROWN R. Hepatitis C virus[J]. Trends Microbiol, 2019, 27(4): 379-380. DOI: 10.1016/j.tim.2019.01.001.
[2]
THOMAS DL. Global control of hepatitis C: where challenge meets opportunity[J]. Nat Med, 2013, 19(7): 850-858. DOI: 10.1038/nm.3184.
[3]
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176. DOI: 10.1016/S2468-1253(16)30181-9.
[4]
SUN HQ, XIAO GX, GUO Y, et al. Spatial clustering and changing trend of hepatitis C prevalence during 2008-2012 in China[J]. China Public Health, 2014, 30(3): 286-289. DOI: 10.11847/zgggws2014-30-03-10.
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
YANG J, RAO HY. EASL recommendations on treatment of hepatitis C: Final update of the series (2020)[J]. J Clin Hepatol, 2020, 36(12): 2681-2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.
WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(2): 127-134. DOI: 10.1016/S2468-1253(18)30343-1.
[10]
ZHOU Q, YANG LH, JIANG FQ. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. J Clin Hepatol, 2021, 37(8): 1836-1840. DOI: 10.3969/j.issn.1001-5256.2021.08.018.
GAO Y, YANG J, SUN F, et al. Prevalence of anti-HCV antibody among the general population in mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(3): ofz040. DOI: 10.1093/ofid/ofz040.
[12]
CALVARUSO V, PETTA S, CRAXÌ A. Is global elimination of HCV realistic?[J]. Liver Int, 2018, 38(Suppl 1): 40-46. DOI: 10.1111/liv.13668.
[13]
DORE GJ, BAJIS S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(2): 91-92. DOI: 10.1038/s41575-020-00392-3.
[14]
CHEN LN, JIN LZ, SUN LB, et al. Survey and analysis of HCV antibody positivity among 802 community-dwelling adults in Yanbian Prefecture, Jilin Province, China[J]. Chronic Pathematol J, 2013, 14(6): 463-464. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201306023.htm
LITAKER JR, TAMEZ N, LOPEZ BRAY C, et al. Hepatitis C antibody screening among baby boomers by a community-based health insurance company[J]. Popul Health Manag, 2021, 24(4): 492-495. DOI: 10.1089/pop.2020.0214.
[16]
MOORMAN AC, DROBENUIC J, KAMILI S. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007-2012[J]. J Clin Virol, 2017, 89: 1-4. DOI: 10.1016/j.jcv.2017.01.007.
[17]
CUI FQ, ZHUANG H. Progress in prevention and control of viral hepatitis since the establishing of the People's Republic of China[J]. Chin J Hepatol, 2021, 29(8): 725-731. DOI: 10.3760/cma.j.cn501113-20210722-00351.
TRICKEY A, SOOD A, MIDHA V, et al. Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India[J]. Epidemiol Infect, 2019, 147: e283. DOI: 10.1017/S0950268819001705.
PIAO HJ, ZHANG YZ, CHEN N, et al. Comparative study of risk factors for HCV infection between Korean-Chinese and Han nationality in Yanbian area[J]. J Med Sci Yanbian Univ, 2015, 38(4): 333-336. DOI: 10.16068/j.1000-1824.2015.04.035.
PIAO HX, YANG AT, SUN YM, et al. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China[J]. PLoS One, 2014, 9(1): e86190. DOI: 10.1371/journal.pone.0086190.
Zhao Fei, Liu Fei, Wang ZhongFeng, Li HaiJun, Xu HongMei. Vertical transmission of hepatitis B virus: Modes and blocking strategies[J]. J Clin Hepatol, 2019, 35(11): 2557-2560. DOI: 10.3969/j.issn.1001-5256.2019.11.037.
Zhao Fei, Liu Fei, Wang ZhongFeng, Li HaiJun, Xu HongMei. Vertical transmission of hepatitis B virus: Modes and blocking strategies[J]. J Clin Hepatol, 2019, 35(11): 2557-2560. DOI: 10.3969/j.issn.1001-5256.2019.11.037.